Unrelated and alternative donor allogeneic stem cell transplant in patients with relapsed or refractory Hodgkin lymphoma: a systematic review

References

• Kewalramani T, Nimer SD, Zelenetz AD, et al. Progressive disease following autologous transplantation in patients with chemosensitive relapsed or primary refractory Hodgkin's disease or aggressive non-Hodgkin's lymphoma. Bone Marrow Transplant 2003;32:673–679.
   PubMed Web of Science ®Google Scholar
• Paltiel O, Rubinstein C, Or R, et al. Factors associated with survival in patients with progressive disease following autologous transplant for lymphoma. Bone Marrow Transplant 2003;31:565–569.
   PubMed Web of Science ®Google Scholar
• Varterasian M, Ratanatharathorn V, Uberti JP, et al. Clinical course and outcome of patients with Hodgkin's disease who progress after autologous transplantation. Leuk Lymphoma 1995;20:59–65.
   PubMed Web of Science ®Google Scholar
• Vose JM, Bierman PJ, Anderson JR, et al. Progressive disease after high-dose therapy and autologous transplantation for lymphoid malignancy: clinical course and patient follow-up. Blood 1992;80: 2142–2148.
   PubMed Web of Science ®Google Scholar
• Ljungman P, Bregni M, Brune M, et al. Allogeneic and autologous transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe 2009. Bone Marrow Transplant 2010;45:219–234.
   PubMed Web of Science ®Google Scholar
• Baldomero H, Gratwohl M, Gratwohl A, et al. The EBMT activity survey 2009: trends over the past 5 years. Bone Marrow Transplant 2011;46:485–501.
   PubMed Web of Science ®Google Scholar
• Kahl C, Storer BE, Sandmaier BM, et al. Relapse risk in patients with malignant diseases given allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning. Blood 2007;110:2744–2748.
   PubMed Web of Science ®Google Scholar
• Ho VT, Kim HT, Aldridge J, et al. Use of matched unrelated donors compared with matched related donors is associated with lower relapse and superior progression-free survival after reduced-intensity conditioning hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2011;17:1196–1204.
   PubMed Web of Science ®Google Scholar
• Peggs KS, Hunter A, Chopra R, et al. Clinical evidence of a graft-versus-Hodgkin's-lymphoma effect after reduced-intensity allogeneic transplantation. Lancet 2005;365:1934–1941.
   PubMed Web of Science ®Google Scholar
• Porter DL, Connors JM, Van Deerlin VM, et al. Graft- versus-tumor induction with donor leukocyte infusions as primary therapy for patients with malignancies. J Clin Oncol 1999;17:1234.
   PubMed Web of Science ®Google Scholar
• Copelan EA. Hematopoietic stem-cell transplantation. N Engl J Med 2006;354:1813–1826.
   PubMed Web of Science ®Google Scholar
• Couriel D, Caldera H, Champlin R, et al. Acute graft-versus-host disease: pathophysiology, clinical manifestations, and management. Cancer 2004;101:1936–1946.
   PubMed Web of Science ®Google Scholar
• Lee SJ. New approaches for preventing and treating chronic graft-versus-host disease. Blood 2005;105:4200–4206.
   PubMed Web of Science ®Google Scholar
• Allogene Stammzelltransplantation mit nicht verwandtem Spender bei der Indikation Hodgkin-Lymphom: Abschlussbericht; Auftrag N05-03F; Version 1.0 [Internet]. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen, 2010-[cited 12.12.2010]. Available from: https://www.iqwig.de/download/N05-03F_Abschluss bericht_Allogene_Stammzelltransplantation_beim_Hodgkin-Lymphom.pdf
   Google Scholar
• Allogene Stammzelltransplantation mit nicht verwandtem Spender bei der Indikation Hodgkin-Lymphom: Berichtsplan; Auftrag N05-03F; Version 1.0 [Internet]. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen, 2009-[cited 12.02.2009]. Available from: https://www.iqwig.de/download/N05-03F_BP_Version_1_0_Allogene_Stammzelltransplantation_beim_Hodgkin_Lymphom.pdf
   Google Scholar
• Anderlini P, Saliba R, Acholonu S, et al. Fludarabine-melphalan as a preparative regimen for reduced-intensity conditioning allogeneic stem cell transplantation in relapsed and refractory Hodgkin's lymphoma: the updated M.D. Anderson Cancer Center experience. Haematologica 2008;93:257–264.
   Google Scholar
• Anderlini P, Saliba R, Acholonu S, et al. Reduced-intensity allogeneic stem cell transplantation in relapsed and refractory Hodgkin's disease: low transplant-related mortality and impact of intensity of conditioning regimen. Bone Marrow Transplant 2005;35:943–951.
   PubMed Web of Science ®Google Scholar
• Armand P, Kim HT, Ho VT, et al. Allogeneic transplantation with reduced-intensity conditioning for Hodgkin and non-Hodgkin lymphoma: importance of histology for outcome. Biol Blood Marrow Transplant 2008;14:418–425.
   PubMed Web of Science ®Google Scholar
• Burroughs LM, O’Donnell PV, Sandmaier BM, et al. Comparison of outcomes of HLA-matched related, unrelated, or HLA-haploidentical related hematopoietic cell transplantation following nonmyeloablative conditioning for relapsed or refractory Hodgkin lymphoma. Biol Blood Marrow Transplant 2008;14:1279–1287.
   PubMed Web of Science ®Google Scholar
• Baron F, Storb R, Storer BE, et al. Factors associated with outcomes in allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning after failed myeloablative hematopoietic cell transplantation. J Clin Oncol 2006;24:4150–4157.
   PubMed Web of Science ®Google Scholar
• Feinstein LC, Sandmaier BM, Maloney DG, et al. Allografting after nonmyeloablative conditioning as a treatment after a failed conventional hematopoietic cell transplant. Biol Blood Marrow Transplant 2003;9:266–272.
   PubMed Web of Science ®Google Scholar
• Peggs KS, Thomson K, Hart DP, et al. Dose-escalated donor lymphocyte infusions following reduced intensity transplantation: toxicity, chimerism, and disease responses. Blood 2004;103:1548–1556.
   PubMed Web of Science ®Google Scholar
• Peggs KS, Kayani I, Edwards N, et al. Donor lymphocyte infusions modulate relapse risk in mixed chimeras and induce durable salvage in relapsed patients after T-cell-depleted allogeneic transplantation for Hodgkin's lymphoma. J Clin Oncol 2011;29:971–978.
   PubMed Web of Science ®Google Scholar
• Devetten MP, Hari PN, Carreras J, et al. Unrelated donor reduced-intensity allogeneic hematopoietic stem cell transplantation for relapsed and refractory Hodgkin lymphoma. Biol Blood Marrow Transplant 2009;15:109–117.
   PubMed Web of Science ®Google Scholar
• Johansson JE, Remberger M, Lazarevic VL, et al. Allogeneic haematopoietic stem-cell transplantation with reduced intensity conditioning for advanced stage Hodgkin's lymphoma in Sweden: high incidence of post transplant lymphoproliferative disorder. Bone Marrow Transplant 2011;46:870–875.
   PubMed Web of Science ®Google Scholar
• Rambaldi A, Bacigalupo A, Fanin R, et al. Outcome of patients activating an unrelated donor search: the impact of transplant with reduced intensity conditioning in a large cohort of consecutive high-risk patients. Leukemia 2012;26:1779–1785.
   PubMed Web of Science ®Google Scholar
• Tomblyn M, Brunstein C, Burns LJ, et al. Similar and promising outcomes in lymphoma patients treated with myeloablative or nonmyeloablative conditioning and allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant 2008;14:538–545.
   PubMed Web of Science ®Google Scholar
• Bachanova V, Brunstein CG, Burns LJ, et al. Fewer infections and lower infection-related mortality following non-myeloablative versus myeloablative conditioning for allotransplantation of patients with lymphoma. Bone Marrow Transplant 2009;43:237–244.
   PubMed Web of Science ®Google Scholar
• Majhail NS, Weisdorf DJ, Wagner JE, et al. Comparable results of umbilical cord blood and HLA-matched sibling donor hematopoietic stem cell transplantation after reduced-intensity preparative regimen for advanced Hodgkin lymphoma. Blood 2006;107: 3804–3807.
   PubMed Web of Science ®Google Scholar
• Brunstein CG, Cantero S, Cao Q, et al. Promising progression- free survival for patients low and intermediate grade lymphoid malignancies after nonmyeloablative umbilical cord blood transplantation. Biol Blood Marrow Transplant 2009;15:214–222.
   PubMed Web of Science ®Google Scholar
• Rodrigues CA, Sanz G, Brunstein CG, et al. Analysis of risk factors for outcomes after unrelated cord blood transplantation in adults with lymphoid malignancies: a study by the Eurocord-Netcord and Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. J Clin Oncol 2009;27:256–263.
   PubMed Web of Science ®Google Scholar
• Chen R, Palmer JM, Popplewell L, et al. Reduced intensity allogeneic hematopoietic cell transplantation can induce durable remission in heavily pretreated relapsed Hodgkin lymphoma. Ann Hematol 2011;90:803–808.
   PubMed Web of Science ®Google Scholar
• Sureda A, Canals C, Arranz R, et al. Allogeneic stem cell transplantation after reduced intensity conditioning in patients with relapsed or refractory Hodgkin's lymphoma. Results of the HDR-ALLO study-a prospective clinical trial by the Grupo Espanol de Linfomas/ Trasplante de Medula Osea (GEL/TAMO) and the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. Haematologica 2012;97:310–317.
   PubMed Web of Science ®Google Scholar
• Schetelig J, Bornhauser M, Schmid C, et al. Matched unrelated or matched sibling donors result in comparable survival after allogeneic stem-cell transplantation in elderly patients with acute myeloid leukemia: a report from the cooperative German Transplant Study Group. J Clin Oncol 2008;26:5183–5191.
   PubMed Web of Science ®Google Scholar
• Michallet M, Sobh M, Milligan D, et al. The impact of HLA matching on long-term transplant outcome after allogeneic hematopoietic stem cell transplantation for CLL: a retrospective study from the EBMT registry. Leukemia 2010;24:1725–1731.
   PubMed Web of Science ®Google Scholar
• Dreger P, Dohner H, Ritgen M, et al. Allogeneic stem cell transplantation provides durable disease control in poor-risk chronic lymphocytic leukemia: long-term clinical and MRD results of the German CLL Study Group CLL3X trial. Blood 2010;116:2438–2447.
   PubMed Web of Science ®Google Scholar
• Thomson KJ, Peggs KS, Smith P, et al. Superiority of reduced-intensity allogeneic transplantation over conventional treatment for relapse of Hodgkin's lymphoma following autologous stem cell transplantation. Bone Marrow Transplant 2008;41:765–770.
   PubMed Web of Science ®Google Scholar
• Castagna L, Sarina B, Todisco E, et al. Allogeneic stem cell transplantation compared with chemotherapy for poor-risk Hodgkin lymphoma. Biol Blood Marrow Transplant 2009;15:432–438.
   PubMed Web of Science ®Google Scholar
• Sarina B, Castagna L, Farina L, et al. Allogeneic transplantation improves the overall and progression-free survival of Hodgkin's lymphoma patients relapsing after autologous transplantation: a retrospective study based on the time of HLA typing and donor availability. Blood 2010;115:3671–3677.
   PubMed Web of Science ®Google Scholar
• Lee SJ, Klein J, Haagenson M, et al. High-resolution donor-recipient HLA matching contributes to the success of unrelated donor marrow transplantation. Blood 2007;110:4576–4583.
   PubMed Web of Science ®Google Scholar
• Murphy F, Sirohi B, Cunningham D. Stem cell transplantation in Hodgkin lymphoma. Expert Rev Anticancer Ther 2007;7:297–306.
   PubMed Web of Science ®Google Scholar
• Chakraverty R, Mackinnon S. Allogeneic transplantation for lymphoma. J Clin Oncol 2011;29:1855–1863.
   Google Scholar
• Corradini P, Sarina B, Farina L. Allogeneic transplantation for Hodgkin's lymphoma. Br J Haemato 2010;152:261–272.
   PubMed Web of Science ®Google Scholar
• Carella AM. Role of hematopoietic stem cell transplantation in relapsed/refractory hodgkin lymphoma. Mediterr J Hematol Infect Dis 2012;4:e2012059.
   PubMedGoogle Scholar